CRYOPORT, INC. (CYRX) Current Ratio
- Current ratio · latest quarter: Value 2.08×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.08× | Current assets / current liabilities. $460.20M ÷ $221.04M ≈ 2.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 460.20M USD | Assets, Current |
| Current obligations | 221.04M USD | Liabilities, Current |
| Cash and equivalents | 269.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 36.45M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 21.51M USD | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $460.20M | $221.04M | $269.27M | (m) | $36.45M | $21.51M | (m) | (m) | 2.08× |
| 2026-03-31 | $470.54M | $224.87M | $272.91M | (m) | $39.00M | $21.75M | (m) | (m) | 2.09× |
| 2025-12-31 | $476.17M | $219.02M | $250.49M | (m) | $33.36M | $23.19M | (m) | (m) | 2.17× |
| 2025-09-30 | $484.84M | $30.75M | $255.81M | (m) | $34.91M | $23.33M | (m) | (m) | 15.77× |
| 2025-06-30 | $489.49M | $30.15M | $243.42M | (m) | $33.41M | $23.04M | (m) | (m) | 16.24× |
| 2025-03-31 | $411.28M | $74.03M | $36.10M | (m) | $28.37M | $23.34M | (m) | (m) | 5.56× |
| 2024-12-31 | $341.57M | $64.56M | $34.14M | (m) | $25.30M | $21.48M | (m) | (m) | 5.29× |
| 2024-09-30 | $350.34M | $61.44M | $44.66M | (m) | $43.46M | $23.55M | (m) | (m) | 5.70× |
| 2024-06-30 | $501.99M | $59.88M | $46.46M | (m) | $40.16M | $23.61M | (m) | (m) | 8.38× |
| 2024-03-31 | $525.70M | $48.98M | $49.66M | (m) | $41.25M | $25.02M | (m) | (m) | 10.73× |
| 2023-12-31 | $535.11M | $45.61M | $46.35M | (m) | $42.07M | $26.21M | (m) | (m) | 11.73× |
| 2023-09-30 | $549.14M | $44.91M | $59.47M | (m) | $42.63M | $29.10M | (m) | (m) | 12.23× |
| 2023-06-30 | $585.19M | $40.25M | $67.31M | (m) | $43.08M | $28.82M | (m) | (m) | 14.54× |
| 2023-03-31 | $604.63M | $41.58M | $38.54M | (m) | $45.57M | $26.49M | (m) | (m) | 14.54× |
| 2022-12-31 | $604.18M | $40.85M | $36.59M | (m) | $43.86M | $27.68M | (m) | (m) | 14.79× |
| 2022-09-30 | $609.13M | $40.73M | $30.72M | (m) | $44.42M | $24.54M | (m) | (m) | 14.96× |
| 2022-06-30 | $625.84M | $44.05M | $37.03M | (m) | $43.90M | $23.07M | (m) | (m) | 14.21× |
| 2022-03-31 | $665.77M | $44.44M | $134.45M | (m) | $35.84M | $22.06M | (m) | (m) | 14.98× |
| 2021-12-31 | $693.52M | $42.65M | $139.10M | (m) | $39.41M | $16.50M | (m) | (m) | 16.26× |
| 2021-09-30 | $410.38M | $41.07M | $43.68M | (m) | $38.46M | $13.48M | (m) | (m) | 9.99× |
| 2021-06-30 | $411.75M | $38.15M | $60.36M | (m) | $38.10M | $11.66M | (m) | (m) | 10.79× |
| 2021-03-31 | $419.75M | $37.87M | $85.49M | (m) | $36.50M | $11.54M | (m) | (m) | 11.08× |
| 2020-12-31 | $147.16M | $35.02M | $36.87M | (m) | $31.38M | $10.54M | (m) | (m) | 4.20× |
| 2020-09-30 | $212.64M | $13.19M | $161.99M | (m) | $7.78M | $476.62K | (m) | (m) | 16.13× |
| 2020-06-30 | $216.69M | $9.44M | $44.33M | (m) | $7.04M | $538.38K | (m) | (m) | 22.95× |
| 2020-03-31 | $105.04M | $7.07M | $50.62M | (m) | $6.14M | $464.59K | (m) | (m) | 14.86× |
| 2019-12-31 | $102.97M | $5.46M | $47.23M | (m) | $7.10M | $474.00K | (m) | (m) | 18.85× |
| 2019-09-30 | $102.22M | $5.71M | $44.59M | (m) | $7.50M | $350.92K | (m) | (m) | 17.91× |
| 2019-06-30 | $101.67M | $5.73M | $80.64M | (m) | $6.10M | $306.44K | (m) | (m) | 17.73× |
| 2019-03-31 | $52.45M | $4.53M | $32.77M | (m) | $4.21M | $227.09K | (m) | (m) | 11.57× |
| 2018-12-31 | $51.77M | $3.06M | $37.33M | (m) | $3.54M | $220.51K | (m) | (m) | 16.91× |
| 2018-09-30 | $27.94M | $2.79M | $13.85M | (m) | $3.20M | $130.30K | (m) | (m) | 10.03× |
| 2018-06-30 | $24.23M | $3.13M | $20.01M | (m) | $3.62M | $97.29K | (m) | (m) | 7.73× |
| 2018-03-31 | $22.04M | $2.44M | $18.99M | (m) | $2.39M | $121.93K | (m) | (m) | 9.02× |
| 2017-12-31 | $17.30M | $2.20M | $15.04M | (m) | $1.63M | $114.80K | (m) | (m) | 7.85× |
| 2017-09-30 | $17.22M | $1.77M | $15.40M | (m) | $1.46M | $90.25K | (m) | (m) | 9.72× |
| 2017-06-30 | $14.49M | $1.97M | $12.85M | (m) | $1.25M | $72.62K | (m) | (m) | 7.36× |
| 2017-03-31 | $16.39M | $2.63M | $14.53M | (m) | $1.47M | $70.96K | (m) | (m) | 6.22× |
| 2016-12-31 | $6.10M | $2.23M | $4.52M | (m) | $1.20M | $89.50K | (m) | (m) | 2.73× |
| 2016-09-30 | $4.25M | $2.29M | $2.56M | (m) | $1.00M | $82.19K | (m) | (m) | 1.85× |
| 2016-06-30 | $5.91M | $2.61M | $4.53M | (m) | $1.02M | $83.54K | (m) | (m) | 2.27× |
| 2016-03-31 | $4.13M | $2.17M | $2.79M | (m) | $1.02M | $69.80K | (m) | (m) | 1.90× |
| 2015-12-31 | $6.21M | $2.47M | $5.25M | (m) | $616.78K | $52.88K | (m) | (m) | 2.51× |
| 2015-09-30 | $8.03M | $2.20M | $7.06M | (m) | $702.91K | $79.23K | (m) | (m) | 3.65× |
| 2015-06-30 | $3.51M | $1.97M | $2.39M | (m) | $757.44K | $104.80K | (m) | (m) | 1.78× |
| 2015-03-31 | $2.16M | $3.00M | $1.41M | (m) | $589.70K | $69.68K | (m) | (m) | 0.72× |
| 2014-12-31 | $1.37M | $2.98M | $773.92K | (m) | $407.46K | $66.96K | (m) | (m) | 0.46× |
| 2014-09-30 | $655.54K | $2.58M | $103.34K | (m) | $408.08K | $58.80K | (m) | (m) | 0.25× |
| 2014-06-30 | $783.39K | $2.38M | $170.50K | (m) | $492.87K | $38.60K | (m) | (m) | 0.33× |
| 2014-03-31 | $1.11M | $4.01M | $369.58K | (m) | $515.83K | $29.70K | (m) | (m) | 0.28× |
| 2013-12-31 | $988.38K | $1.77M | $219.97K | (m) | $635.69K | $30.01K | (m) | (m) | 0.56× |
| 2013-09-30 | $1.00M | $1.04M | $532.47K | (m) | $387.67K | $43.30K | (m) | (m) | 0.96× |
| 2013-06-30 | $823.11K | $3.38M | $227.53K | (m) | $357.70K | $52.86K | (m) | (m) | 0.24× |
| 2013-03-31 | $958.30K | $2.50M | $563.10K | (m) | $217.10K | $39.21K | (m) | (m) | 0.38× |
| 2012-12-31 | $898.73K | $952.18K | $585.11K | (m) | $201.14K | $55.46K | (m) | (m) | 0.94× |
| 2012-09-30 | $1.93M | $713.09K | $1.67M | (m) | $170.37K | $55.92K | (m) | (m) | 2.71× |
| 2012-06-30 | $3.20M | $596.02K | $2.97M | (m) | $144.77K | $47.51K | (m) | (m) | 5.37× |
| 2012-03-31 | $5.13M | $1.11M | $4.62M | (m) | $146.12K | $51.75K | (m) | (m) | 4.63× |
| 2011-12-31 | $3.06M | $2.22M | $2.80M | (m) | $83.71K | $47.13K | (m) | (m) | 1.38× |
| 2011-09-30 | $5.36M | $2.53M | $4.95M | (m) | $111.39K | $42.68K | (m) | (m) | 2.12× |
| 2011-06-30 | $7.66M | $3.18M | $7.06M | (m) | $75.94K | $44.96K | (m) | (m) | 2.41× |
| 2011-03-31 | $10.00M | $3.24M | $9.28M | (m) | $55.79K | $44.22K | (m) | (m) | 3.09× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |